Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Medicure Inc. (V:MPH)

Business Focus: Pharmaceuticals

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for MPH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 10, 2019 17:30 ET
Medicure Announces Appoinment of Dr. Neil Owens as President and Chief Operating Officer
WINNIPEG, June 10, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJD.PK), a pharmaceutical company, today announced that Dr. Neil Owens has been appointed President and Chief Operating Officer of the Company effective July 1, 2019.  In this capacity, Dr. Owens will be responsible for implementing the Company's strategic plans, and overseeing day-to-day operations, including the advancement and management of new and existing pharmaceutical products. Dr. Albert Friesen has served as the Company's President since May of 2016 and will continue to serve as Chief Exec
Read full article
May 30, 2019 09:30 ET
Medicure Announces Renewal of its Normal Course Issuer Bid
WINNIPEG, May 30, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.17
--
--
Price to Sales - TTM
2.72
8.89
16.93
Price to Book - most recent quarter
0.96
3.06
3.28
Price to Cash Flow per share - TTM
18.73
10.07
13.83
Price to Free Cash Flow per share - TTM
--
9.14
12.12
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 31, 20196,1435,798
May 15, 2019345-2,103
Apr 30, 20192,4481,635
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $MPH.CA MPH.V

  • No tweets found

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $MPH.CA MPH.V

  • No tweets found